Search

Your search keyword '"Weimer, L"' showing total 129 results

Search Constraints

Start Over You searched for: Author "Weimer, L" Remove constraint Author: "Weimer, L"
129 results on '"Weimer, L"'

Search Results

3. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

4. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

6. Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

7. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

9. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study

11. Corrigendum to 'Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV' [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

12. L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV

14. Nusinersen versus sham control in infantile-onset spinal muscular atrophy

15. HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study

16. Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection

17. Limited occurrence of new grade 3-4 toxicity events with salvage regimens based on raltegravir and /or maraviroc: 96 weeks data from the ISS NIA cohort study

19. Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) Study

22. Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors

24. Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy

27. A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation.

28. Randomized controlled phase II trial of glatiramer acetate in ALS

32. A Randomized, Double-Blind Trial on the Use of a Triple Combination Including Nevirapine, a Nonnucleoside Reverse Transcriptase HIV Inhibitor, in Antiretroviral-Naive Patients With Advanced Disease

33. Microstrip Discontinuity Models to 60 GHz

34. A Randomized Trial (ISS 902) of Didanosine versus Zidovudine in Previously Untreated Patients with Mildly Symptomatic Human Immunodeficiency Virus Infection

36. A Reduced Grade of Liver Fibro-steatosis after Raltegravir, Maraviroc and Fosamprenavir in an HIV/HCV Co-infected Patient with Chronic Hepatitis, Cardiomyopathy, Intolerance to Nelfinavir and a Marked Increase of Serum Creatine Phosphokinase Levels...

39. A Reduction Grade of Lipodystrophy and Limited Side Effects after HAART Regimen with Raltegravir, Lamivudine, Darunavir and Ritonavir in an HIV-1 Infected Patient after Six Years of Antiretroviral Therapy.

40. Long-term Maraviroc Therapy and Limited Side Effects in an HIV-1 Experienced Patient: Six Years of Antiretroviral Observation.

42. Secretion of proinflammatory cytokines by human conjunctival epithelial cells.

46. Sustained Increase of Serum Creatine Phosphokinase Levels and Progressive Muscle Abnormalities Associated with Raltegravir Use during a 32-week Follow-up in an HIV-1 Experienced Patient on Simplified HAART Regimen, Intolerant to Protease Inhibitors...

48. Three-years follow up of raltegravir and/or maraviroc-based regimens in patients experienced to PI, NRTI, NNRTI. Update from the ISS-NIA cohort

49. Virological response to treatment in patient who start raltegravir in combination with newer agents in current clinical practice

Catalog

Books, media, physical & digital resources